Around 2003, Abbott raised the price of the Norvir course from either $1.71 by the day to $8.57 by the day, leading to claims of price gouging by patients' groups & a select few members of Congress. Consumer class action Essential Inventions petitioned a NIH to override a Norvir patent, however the NIH announced in August 4, 2004 that it will non invoke its legal correct to allow generic production of Norvir, citing expected adverse results on the pharmaceutical market.